CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Grant or award SVP, Chief Marketing Officer acquired 30,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 60,000 shares (grant or award)
- 4 Grant or award Chief Corp. Affairs Officer acquired 30,000 shares (grant or award)
- 4 Grant or award SVP, Business Development acquired 30,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale SVP & Chief Commercial Officer sold 1,155 shares at $16.06 ($18,551)
- 4 Open-market sale President and CEO sold 9,467 shares at $16.00 ($151,493)
- 4 Open-market sale EVP & Chief Financial Officer sold 4,020 shares at $15.94 ($64,086)
- 4 Open-market sale SVP, Business Development sold 4,020 shares at $15.93 ($64,021)
- 4 Open-market sale President and CEO sold 142,409 shares at an average $16.95 ($2,413,729)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 15,000 shares at $14.85 ($222,750)
- 4 Grant or award SVP, Chief Marketing Officer acquired 30,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale SVP & General Counsel sold 2,575 shares at $14.69 ($37,829)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
Page 9 of 29 · 579 filings